Connor, Clark & Lunn Investment Management (CC&L)’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-98,037
| Closed | -$156K | – | 1768 |
|
|
2024
Q1 | $156K | Buy |
+98,037
| New | +$156K | ﹤0.01% | 1428 |
|
|
2023
Q3 | – | Sell |
-121,685
| Closed | -$315K | – | 1595 |
|
|
2023
Q2 | $315K | Sell |
121,685
-72,466
| -37% | -$188K | ﹤0.01% | 1096 |
|
|
2023
Q1 | $792K | Buy |
194,151
+39,741
| +26% | +$162K | ﹤0.01% | 776 |
|
|
2022
Q4 | $775K | Buy |
154,410
+43,711
| +39% | +$219K | ﹤0.01% | 771 |
|
|
2022
Q3 | $1.45M | Buy |
110,699
+74,646
| +207% | +$976K | 0.01% | 569 |
|
|
2022
Q2 | $462K | Buy |
+36,053
| New | +$462K | ﹤0.01% | 800 |
|